Skinny Labeling Compliance and Inducement and Equitable Estoppel
The Federal Circuit denied a petition for en banc review of a panel opinion finding induced infringement liability despite the manufacturer’s adherence to skinny labeling rules, and suggested equitable estoppel was the appropriate vehicle. GlaxoSmithKline LLC v. Teva Pharms